Zack Gong

Cooley advised Aclaris Therapeutics (Nasdaq: ACRS), a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, on its exclusive license agreement with Biosion and $80 million private placement.

Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company, for an upfront payment of $300 million, plus success-based development and commercial milestone payments totaling up to $550 million.

Cooley advised the underwriters of Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, on its upsized $293 million initial public offering.

Cooley advised Jiangsu Hengrui Pharmaceuticals, one of the largest pharmaceutical companies in China, on its licensing of global rights (excluding Greater China) for the development, production and commercialization of three of its proprietary glucagon-like peptide-1 (GLP-1) drugs to Hercules CM Newco, a newly established Delaware company.

Cooley advised ARCH Venture Partners, which co-led a $1 billion Series A funding round in Xaira Therapeutics. Partners Colleen Badgley, Danielle Naftulin and Dave Peinsipp led the Cooley team advising ARCH, a venture capital firm catalyzing discoveries that prevent, detect and cure disease.